A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer
Pembrolizumab SC substantially reduces active HCP time and patient chair time versus pembrolizumab IV. Time liberated for HCPs could be reallocated toward additional patient care activities, while optimized chair utilization could improve overall healthcare efficiency.
Authors
- Renata Eiras (ORCID: https://orcid.org/0000-0003-2169-4358)
- Gustavo Vasconcelos Alves (ORCID: https://orcid.org/0000-0003-4985-5555)
- E De Cock (ORCID: https://orcid.org/0000-0002-1623-9169)
- Sabine Oskar (ORCID: https://orcid.org/0000-0002-8942-7734)
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- M. Catherine Pietanza (ORCID: https://orcid.org/0000-0002-5663-661X)
- Cecilia Lourdudoss (ORCID: https://orcid.org/0000-0001-8925-1751)
- Gastón Lucas Martinengo
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Syneos Health (United States) (US)
- Centro Científico Tecnólogico - Rosario (AR)
- Hospital Nossa Senhora da Conceição (BR)
- Vall d'Hebron Hospital Universitari (ES)
- Syneos Health (India) (IN)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s12325-025-03365-7
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05